These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35352186)

  • 1. Current Approaches for Dissolution Similarity Assessment, Requirements, and Global Expectations.
    Abend AM; Zhang L; Fredro-Kumbaradzi E; Hoffelder T; Cohen MJ; Anand O; Delvadia P; Mandula H; Zhang Z; Kotzagiorgis E; Lum S; Pereira VG; Barker A; Lavrich D; Kraemer J; Sharp-Suarez S
    AAPS J; 2022 Mar; 24(3):50. PubMed ID: 35352186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Dissolution Profiles Similarity Assessment in Support of Drug Product Quality: What, How, When-Workshop Summary Report.
    Suarez-Sharp S; Abend A; Hoffelder T; Leblond D; Delvadia P; Kovacs E; Diaz DA
    AAPS J; 2020 May; 22(4):74. PubMed ID: 32430592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report.
    Abend A; Heimbach T; Cohen M; Kesisoglou F; Pepin X; Suarez-Sharp S
    AAPS J; 2018 Apr; 20(3):60. PubMed ID: 29633092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DISSOLUTION PROFILE SIMILARITY ANALYSES-STATISTICAL PRINCIPLES, METHODS AND CONSIDERATIONS.
    Hoffelder T; Leblond D; Van Alstine L; Diaz DA; Suarez-Sharp S; Witkowski K; Altan S; Reynolds J; Bergeron Z; Lief K; Zheng Y; Abend A
    AAPS J; 2022 Apr; 24(3):54. PubMed ID: 35386051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution Profile Similarity Assessment-Best Practices, Decision Trees and Global Harmonization.
    Abend AM; Hoffelder T; Cohen MJ; Van Alstine L; Diaz DA; Fredro-Kumbaradzi E; Reynolds J; Zheng Y; Witkowski K; Heimbach T
    AAPS J; 2023 Apr; 25(3):44. PubMed ID: 37084114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations?
    Diaz DA; Colgan ST; Langer CS; Bandi NT; Likar MD; Van Alstine L
    AAPS J; 2016 Jan; 18(1):15-22. PubMed ID: 26428517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
    Mackie C; Arora S; Seo P; Moody R; Rege B; Pepin X; Heimbach T; Tannergren C; Mitra A; Suarez-Sharp S; Borges LN; Kijima S; Kotzagiorgis E; Malamatari M; Veerasingham S; Polli JE; Rullo G
    Mol Pharm; 2024 May; 21(5):2065-2080. PubMed ID: 38600804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution Testing in Drug Product Development: Workshop Summary Report.
    Abend A; Curran D; Kuiper J; Lu X; Li H; Hermans A; Kotwal P; Diaz DA; Cohen MJ; Zhang L; Stippler E; Drazer G; Lin Y; Raines K; Yu L; Coutant CA; Grady H; Krämer J; Pope-Miksinski S; Suarez-Sharp S
    AAPS J; 2019 Jan; 21(2):21. PubMed ID: 30690680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report.
    Mitra A; Suarez-Sharp S; Pepin XJH; Flanagan T; Zhao Y; Kotzagiorgis E; Parrott N; Sharan S; Tistaert C; Heimbach T; Zolnik B; Sjögren E; Wu F; Anand O; Kakar S; Li M; Veerasingham S; Kijima S; Lima Santos GM; Ning B; Raines K; Rullo G; Mandula H; Delvadia P; Dressman J; Dickinson PA; Babiskin A
    J Pharm Sci; 2021 Feb; 110(2):594-609. PubMed ID: 33152375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing Clinically Relevant Dissolution Specifications for Oral Drug Products-Industrial and Regulatory Perspectives.
    McAllister M; Flanagan T; Boon K; Pepin X; Tistaert C; Jamei M; Abend A; Kotzagiorgis E; Mackie C
    Pharmaceutics; 2019 Dec; 12(1):. PubMed ID: 31878006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical Considerations Concerning Dissimilar Regulatory Requirements for Dissolution Similarity Assessment. The Example of Immediate-Release Dosage Forms.
    Jasińska-Stroschein M; Kurczewska U; Orszulak-Michalak D
    J Pharm Sci; 2017 May; 106(5):1275-1284. PubMed ID: 28088455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations.
    Uppoor VR
    J Control Release; 2001 May; 72(1-3):127-32. PubMed ID: 11389991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
    Tan DCT; Khong YM; Mount S; Galella E; Mitra B; Charlton S; Kuhli M; Ternik R; Walsh J; Rajapakshe A; Thompson K; Mehrotra S; Santangelo M; Liu J; Dixit T; Schaufelberger D; Jamzad S; Klein S; Hoag SW; Wang J; Fletcher EP; Khurana M; Alexander J; Radden E; Sood R; Selen A
    Eur J Pharm Biopharm; 2021 Jul; 164():54-65. PubMed ID: 33878432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing Product Quality: a Summary of the Inaugural FDA/PQRI Conference.
    Yu LX; Baker J; Berlam SC; Boam A; Brandreth EJ; Buhse L; Cosgrove T; Doleski D; Ensor L; Famulare J; Ganapathy M; Grampp G; Hussong D; Iser R; Johnston G; Kesisoglou F; Khan M; Kozlowski S; Lacana E; Lee SL; Miller S; Miksinski SP; Moore CM; Mullin T; Raju GK; Raw A; Rosencrance S; Rosolowsky M; Stinavage P; Thomas H; Wesdyk R; Windisch J; Vaithiyalingam S
    AAPS J; 2015 Jul; 17(4):1011-8. PubMed ID: 25840884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Dissolution Profiles: A Statistician's Perspective.
    Hoffelder T
    Ther Innov Regul Sci; 2018 Jul; 52(4):423-429. PubMed ID: 29714555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Dissolution Similarity Assessment Methods for Products with Large Variations: f
    Yoshida H; Shibata H; Izutsu KI; Goda Y
    Biol Pharm Bull; 2017; 40(5):722-725. PubMed ID: 28458360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory Perspectives on Strength-Dependent Dissolution Profiles and Biowaiver Approaches for Immediate Release (IR) Oral Tablets in New Drug Applications.
    Suarez-Sharp S; Delvadia PR; Dorantes A; Duan J; Externbrink A; Gao Z; Ghosh T; Miksinski SP; Seo P
    AAPS J; 2016 May; 18(3):578-88. PubMed ID: 26928450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
    Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
    Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
    Davit BM; Kanfer I; Tsang YC; Cardot JM
    AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.